$MS··On the fence
Examining MS: A Look at Recent Developments
When I stumbled upon the news of Immunic naming Erik Lundgren as CEO, it caught my attention. The company is advancing its Phase 3 trials in multiple sclerosis MS, a disease that'...
2 posts
When I stumbled upon the news of Immunic naming Erik Lundgren as CEO, it caught my attention. The company is advancing its Phase 3 trials in multiple sclerosis MS, a disease that'...
Morgan Stanley MS caught my attention today due to its inclusion in a couple of recent stock watchlists. It's always interesting to see which companies are being highlighted, and...